

Takashi Taga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7432267/publications.pdf>

Version: 2024-02-01

136
papers

1,777
citations

430442

18
h-index

315357

38
g-index

142
all docs

142
docs citations

142
times ranked

2364
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 3207-3219.	2.5	7
2	Identification of Germline Non-coding Deletions in XIAP Gene Causing XIAP Deficiency Reveals a Key Promoter Sequence. <i>Journal of Clinical Immunology</i> , 2022, 42, 559-571.	2.0	6
3	Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group. <i>International Journal of Hematology</i> , 2022, 116, 131-138.	0.7	5
4	Familial hemophagocytic lymphohistiocytosis syndrome due to lysinuric protein intolerance: a patient with a novel compound heterozygous pathogenic variant in SLC7A7. <i>International Journal of Hematology</i> , 2022, 116, 635-638.	0.7	3
5	Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML05 study. <i>British Journal of Haematology</i> , 2021, 193, 176-180.	1.2	3
6	The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML05R study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28736.	0.8	11
7	Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. <i>British Journal of Haematology</i> , 2021, 192, e7-e11.	1.2	0
8	Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28980.	0.8	0
9	Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. <i>Leukemia</i> , 2021, 35, 2508-2516.	3.3	5
10	Topoisomerase II ² immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group. <i>Brain Tumor Pathology</i> , 2021, 38, 109-121.	1.1	1
11	Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1859-1865.	1.3	4
12	Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome. <i>Leukemia</i> , 2021, 35, 1480-1484.	3.3	11
13	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2021, , .	1.7	10
14	Droplet digital polymerase chain reaction assay for the detection of the minor clone of <i>KIT</i> D816V in paediatric acute myeloid leukaemia especially showing <i>RUNX1-RUNX1T1</i> transcripts. <i>British Journal of Haematology</i> , 2021, 194, 414-422.	1.2	2
15	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG). <i>British Journal of Haematology</i> , 2021, 194, 718-729.	1.2	3
16	Hematopoietic Cell Transplantation Rescues Inflammatory Bowel Disease and Dysbiosis of Gut Microbiota in XIAP Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3767-3780.	2.0	15
17	Using the <i>in vitro</i> drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
18	Clonal Evolution Pattern and Prognostic Significance of Clonal Architecture in KMT2A-Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2358-2358.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Highly sensitive detection of <i>GATA1</i> mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 160-167.	1.5	8
20	Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. <i>British Journal of Haematology</i> , 2020, 188, 528-539.	1.2	20
21	Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. <i>Blood Advances</i> , 2020, 4, 4623-4631.	2.5	7
22	Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28692.	0.8	8
23	Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey. <i>EJHaem</i> , 2020, 1, 86-93.	0.4	3
24	EVII triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase. <i>Haematologica</i> , 2020, 105, 2118-2129.	1.7	17
25	Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28181.	0.8	3
26	Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
27	Etoposide, Cytarabine and Mitoxantrone- or Fludarabine, Cytarabine and Granulocyte Colony-Stimulating Factor-Based Intensive Reinduction Chemotherapy Is Recommended for Children with Relapsed Acute Myeloid Leukemia: The Results from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R Study. <i>Blood</i> , 2020, 136, 6-6.	0.6	0
28	<i>KRAS</i> mutations Frequently Coexist with High-Risk <i>MLL</i> Fusions and Are Independent Adverse Prognostic Factors in <i>MLL</i> -Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
29	Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. <i>Bone Marrow Transplantation</i> , 2019, 54, 393-401.	1.3	15
30	Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27942.	0.8	2
31	Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML05 clinical trial. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27875.	0.8	12
32	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. <i>Cancer Cell</i> , 2019, 36, 123-138.e10.	7.7	93
33	Registration-directed phase 1/2 trial of irinotecan for pediatric solid tumors. <i>Pediatrics International</i> , 2019, 61, 453-458.	0.2	5
34	Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML 05 study. <i>British Journal of Haematology</i> , 2019, 185, 284-288.	1.2	12
35	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3157-3169.	2.5	51
36	Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>Blood</i> , 2019, 134, 3848-3848.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey. <i>Blood</i> , 2019, 134, 2958-2958.	0.6	1
38	Coexistence and Prognostic Significance of EVI1 Expression and Driver Mutations in KMT2A-Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1409-1409.	0.6	1
39	Predictive Factors of the Development of Leukemia in Patients with Transient Abnormal Myelopoiesis and Down Syndrome: The Jccg Study JPLSG TAM-10. <i>Blood</i> , 2019, 134, 3833-3833.	0.6	1
40	Significant Features of DNA Methylation at Bivalent Promotor and Repressed Polycomb Regions in Pediatric AML-the Jccg Study, JPLSG AML-05-. <i>Blood</i> , 2019, 134, 2739-2739.	0.6	0
41	Clinical Features of Pediatric Acute Myeloid Leukemia with TP53 and CDKN2A/2B copy Number Alterations. <i>Blood</i> , 2019, 134, 2727-2727.	0.6	0
42	Recurrent Gene Mutations in Pediatric Patients with AML By Targeted Sequencing –the Jccg Study, JPLSG AML-05–. <i>Blood</i> , 2019, 134, 2697-2697.	0.6	0
43	The Detection of Minor Clones with Somatic KIT D816V Mutations Using Droplet Digital PCR in Pediatric De Novo AML: AML-05 Trial from the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>Blood</i> , 2019, 134, 1419-1419.	0.6	0
44	Purpura fulminans in congenital protein C deficiency successfully treated with fresh frozen plasma and thrombomodulin. <i>Journal of Dermatology</i> , 2018, 45, e165-e166.	0.6	0
45	Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. <i>International Journal of Hematology</i> , 2018, 107, 586-595.	0.7	20
46	Nationwide survey of therapy-related leukemia in childhood in Japan. <i>International Journal of Hematology</i> , 2018, 108, 91-97.	0.7	12
47	Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia. <i>Pediatrics International</i> , 2018, 60, 41-46.	0.2	13
48	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2018, 107, 201-210.	0.7	15
49	Multiplex fusion gene testing in pediatric acute myeloid leukemia. <i>Pediatrics International</i> , 2018, 60, 47-51.	0.2	12
50	Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2879-2889.	2.5	19
51	Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan. <i>International Journal of Hematology</i> , 2018, 108, 438-442.	0.7	6
52	Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. <i>International Journal of Hematology</i> , 2018, 108, 306-311.	0.7	8
53	RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. <i>Blood</i> , 2018, 131, 2266-2270.	0.6	15
54	Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children’s Cancer Group Multi-Center Seamless Phase II Randomized Trial (JPLSG AML-12). <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 587-593.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Hematopoietic Stem-Cell Transplantation in Children with Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 4632-4632.	0.6	0
56	Comprehensive Analysis of 343 Genes Using Targeted Sequencing Panel By Next-Generation Sequencer in 77 Pediatric AML Patients with Normal and Complex Karyotypes: Jccg Study, JPLSG AML-05. <i>Blood</i> , 2018, 132, 1530-1530.	0.6	0
57	Recurrent Genomic Aberrations of D-Type Cyclins Are Therapeutic Targets of CDK4/6 Inhibitors in t(8;21) and MLL-Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2797-2797.	0.6	0
58	Negative CD19 Expression Is Associated with Inferior Relapse-Free Survival in RUNX1-RUNX1T1-Positive Acute Myeloid Leukemia; The Japanese Pediatric Leukemia/Lymphoma Study Group Experience from the AML-05 Study. <i>Blood</i> , 2018, 132, 2810-2810.	0.6	0
59	Effect of Age on the Prognosis of Molecular Abnormalities in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1506-1506.	0.6	0
60	Sepsis in a 4-Month-Old Boy Due to Carbapenem-Resistant Characterized by AmpC β -Lactamase with Porin Loss. <i>International Journal of Applied & Basic Medical Research</i> , 2018, 8, 263-265.	0.2	1
61	<i>CXCR4</i> mutations are frequently found in pediatric AML patients with t(8;21)/ <i>RUNX1-RUNX1T1</i> and associated with a better prognosis. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 382-393.	1.5	18
62	Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 394-404.	1.5	51
63	Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26491.	0.8	5
64	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1515-1522.	2.0	24
65	Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26411.	0.8	4
66	Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia. <i>Pediatrics International</i> , 2017, 59, 1046-1052.	0.2	7
67	Acute Myeloid Leukemia. , 2017, , 61-85.		0
68	High event-free survival rate with minimum-dose anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group. <i>British Journal of Haematology</i> , 2016, 174, 437-443.	1.2	16
69	<i>CXCR4</i> Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1394-1399.	0.8	11
70	High <i>PRDM16</i> expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to <i>FLT3-ITD</i> , <i>KMT2A-PTD</i> , and <i>NUP98-NSD1</i> : the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial. <i>British Journal of Haematology</i> , 2016, 172, 581-591.	1.2	41
71	Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse. <i>Pediatric Blood and Cancer</i> , 2016, 63, 701-705.	0.8	7
72	Contribution of UGT1A1 variations to chemotherapy-induced unconjugated hyperbilirubinemia in pediatric leukemia patients. <i>Pediatric Research</i> , 2016, 80, 252-257.	1.1	6

#	ARTICLE	IF	CITATIONS
73	Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 476-489.	1.2	60
74	Acute myeloid leukemia in children: Current status and future directions. <i>Pediatrics International</i> , 2016, 58, 71-80.	0.2	71
75	Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan. <i>Pediatric Blood and Cancer</i> , 2016, 63, 248-254.	0.8	33
76	Final report of randomized phase II study of two different outpatient setting regimens, vinorelbine (VNR) with cyclophosphamide (CPA) and temozolomide (TMZ) with etoposide (VP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10550-10550.	0.8	0
77	Identification of Two Distinct Poor Prognostic Subgroups Related to High Expression of BMP2 or PRDM16 in Pediatric AML. <i>Blood</i> , 2016, 128, 2854-2854.	0.6	0
78	Transcriptome Analysis Revealed the Entire Genetic Understanding of Pediatric Acute Myeloid Leukemia with a Normal Karyotype. <i>Blood</i> , 2016, 128, 2850-2850.	0.6	0
79	Clinical and Biological Features of Pediatric Acute Myeloid Leukemia with Primary Induction Failure in the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Study. <i>Blood</i> , 2016, 128, 1610-1610.	0.6	1
80	Adolescents and Young Adults with Acute Myeloid Leukemia Are Associated with Higher Treatment-Related Mortality and Inferior Overall Survival after Allogeneic Hematopoietic Cell Transplantation Compared with Children. <i>Blood</i> , 2016, 128, 4702-4702.	0.6	0
81	Analysis of GATA1 Mutations in Down Syndrome Infants with Transient Abnormal Myelopoiesis and Clinical Impacts of GATA1 Mutation Types: A Report from the JPLSG TAM-10 Study. <i>Blood</i> , 2016, 128, 2865-2865.	0.6	0
82	Retrospective Evaluation of Correlations Between Genetic Backgrounds and Stem Cell Transplantation for De Novo Pediatric Acute Myeloid Leukemia: A Study from the Japan Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Clinical Trial. <i>Blood</i> , 2016, 128, 2904-2904.	0.6	0
83	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	0.6	69
84	<i>CSF3R</i> and <i>CALR</i> mutations in paediatric myeloid disorders and the association of <i>CSF3R</i> mutations with translocations, including t(8; 21). <i>British Journal of Haematology</i> , 2015, 170, 391-397.	1.2	18
85	Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. <i>International Journal of Hematology</i> , 2015, 102, 318-326.	0.7	17
86	Advanced Childhood Testicular Yolk Sac Tumor With Bone Metastasis: A Case Report. <i>Urology</i> , 2015, 85, 671-673.	0.5	3
87	Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>International Journal of Hematology</i> , 2015, 102, 697-701.	0.7	5
88	Prospective Study of 168 Infants with Transient Abnormal Myelopoiesis with Down Syndrome: Japan Pediatric Leukemia/Lymphoma Study Group, TAM-10 Study. <i>Blood</i> , 2015, 126, 1311-1311.	0.6	10
89	High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2583-2583.	0.6	3
90	The Outcome of Relapsed Childhood Core Binding Factor Acute Myeloid Leukemia: A Report from the JPLSG AML-05R Study. <i>Blood</i> , 2015, 126, 2516-2516.	0.6	0

#	ARTICLE	IF	CITATIONS
91	A Combination of EVI1 and PRDM16 Expression Clarified the Clinical Features of Intermediate/High Risk Patients in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1380-1380.	0.6	0
92	Prognostic Significance of CXCR4 Overexpression in Pediatric Acute Myeloid Leukemia with Low-Risk: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>Blood</i> , 2015, 126, 3814-3814.	0.6	0
93	Augmented Consolidation Therapy Based on Minimal Residual Disease (MRD) and Analysis of the Measurement of Sequential MRD in Childhood Acute Lymphoblastic Leukemia : Children's Cancer and Leukemia Study Group of JAPAN (CCLSG), Cclsg ALL 2004 Protocol Study. <i>Blood</i> , 2015, 126, 3724-3724.	0.6	1
94	Distinct Clinical and Cytogenetic Characteristics and Poor Prognosis in Children with Acute Erythroid Leukemia: A Report from the JPLSG AML-05 Study. <i>Blood</i> , 2015, 126, 4945-4945.	0.6	0
95	Detection of Novel Pathogenic Gene Rearrangements in Pediatric Acute Myeloid Leukemia By RNA Sequencing. <i>Blood</i> , 2015, 126, 2575-2575.	0.6	0
96	Undifferentiated sarcoma arising at lower thoracic spine with neuroblastoma-like dumbbell-shaped radiographic appearance in a 1-year-old girl. <i>Spine Journal</i> , 2014, 14, 719-720.	0.6	0
97	Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group. <i>British Journal of Haematology</i> , 2014, 167, 80-86.	1.2	19
98	Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. <i>International Journal of Hematology</i> , 2014, 100, 171-179.	0.7	31
99	EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e225-e227.	1.7	35
100	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. <i>Haematologica</i> , 2014, 99, 299-307.	1.7	34
101	A combination chemotherapy, temozolomide (TMZ) with etoposide (VP), in relapsed or refractory pediatric solid cancer: Preliminary report of randomized phase II study of two different outpatient setting regimens (rPII).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10055-10055.	0.8	0
102	Clinical Features of Patients with ASXL1 and ASXL2 Mutations in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1024-1024.	0.6	0
103	The Prognostic Impact of High MEL1 Gene Expression in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1009-1009.	0.6	0
104	High Event-Free Survival Rate with Minimum-Dose-Anthracycline Treatment in Childhood Acute Promyelocytic Leukemia: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG). <i>Blood</i> , 2014, 124, 956-956.	0.6	0
105	Recombinant Thrombomodulin Safely Controls Disseminated Intravascular Coagulopathy in Acute Promyelocytic Leukemia " Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-P05 Study. <i>Blood</i> , 2014, 124, 5097-5097.	0.6	0
106	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. <i>Blood</i> , 2014, 124, 481-481.	0.6	0
107	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSC). <i>Blood</i> , 2014, 124, 3670-3670.	0.6	0
108	Poor Prognosis Associated with FAB Subtypes M4 and M5 in Japanese Pediatric Acute Myeloid Leukemia Patients with FLT3-ITD. <i>Blood</i> , 2014, 124, 1002-1002.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Outcome of Adolescent and Young Adults with Acute Myeloid Leukemia Treated with Pediatric Protocols: A Report from the 3 Japanese Cooperative Studies. <i>Blood</i> , 2014, 124, 374-374.	0.6	20
110	Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>International Journal of Hematology</i> , 2013, 98, 578-588.	0.7	47
111	CSF3R Gene Mutations In Myeloid Malignancy Of Childhood. <i>Blood</i> , 2013, 122, 1352-1352.	0.6	2
112	Multicenter phase I/II trial of topotecan (T) and ifosfamide (I) combination as second-line therapy for pediatric solid cancer: Phase II results.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10050-10050.	0.8	0
113	Low Frequency and Poor Prognosis Of MLL-Partial Tandem Duplications In Pediatric Acute Myeloid Leukemia Using MLPA Method: The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Trial. <i>Blood</i> , 2013, 122, 1374-1374.	0.6	0
114	Double CEBPA Mutations Are Not Associated With Favorable Clinical Outcome In Pediatric AML: A Report From The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). <i>Blood</i> , 2013, 122, 4942-4942.	0.6	0
115	Comprehensive Fusion Gene Analysis Of Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2013, 122, 2646-2646.	0.6	0
116	Poor Prognosis With Different Induction Rate Was Observed In Children With Acute Myeloid Leukemia and FLT3-ITD According To The ITD/WT Allelic Ratio: A Result From The Japanese Pediatric Leukemia/Lymphoma Study Group. <i>Blood</i> , 2013, 122, 3891-3891.	0.6	0
117	Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. <i>Blood</i> , 2012, 120, 1810-1815.	0.6	46
118	Successful unrelated umbilical cord blood cell transplantation without conditioning for a neonate with severe combined immunodeficiency. <i>Pediatric Transplantation</i> , 2011, 15, E152-5.	0.5	1
119	Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. <i>Pediatric Blood and Cancer</i> , 2011, 57, 36-40.	0.8	35
120	Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma. <i>Journal of Medical Virology</i> , 2011, 83, 1582-1584.	2.5	8
121	Heterogeneity in Infants with Acute Myeloid Leukemia: Retrospective Analysis of a Japanese Nationwide Survey. <i>Blood</i> , 2011, 118, 1477-1477.	0.6	0
122	Refractory / Relapsed Myeloid Leukemia of Down Syndrome Is Resistant to Second-Line Chemotherapy and Hardly Salvaged by Hematopoietic Stem Cell Transplantation: A Retrospective Study by the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG). <i>Blood</i> , 2011, 118, 4276-4276.	0.6	0
123	Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. <i>Blood</i> , 2010, 116, 4631-4638.	0.6	77
124	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. <i>Blood</i> , 2010, 116, 762-762.	0.6	2
125	Low-Dose Cytosine Arabinoside Therapy for Neonates with Down Syndrome (DS) and Transient Leukemia (TL).. <i>Blood</i> , 2010, 116, 1074-1074.	0.6	0
126	Myeloid Leukemia of Down Syndrome: The Results of An International Retrospective Study. <i>Blood</i> , 2010, 116, 2718-2718.	0.6	0

#	ARTICLE	IF	CITATIONS
127	A Rapid Approach for the Integrated Central Review of Acute Myeloid Leukemia Diagnosis In a Nationwide Clinical Trial for Children. <i>Blood</i> , 2010, 116, 4833-4833.	0.6	0
128	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	0.6	383
129	Pediatric primary leptomeningeal lymphoma treated without cranial radiotherapy. <i>Pediatric Blood and Cancer</i> , 2007, 48, 477-478.	0.8	5
130	The Autocrine Loop of Epidermal Growth Factor Receptor-Epidermal Growth Factor/Transforming Growth Factor- β in Malignant Rhabdoid Tumor Cell Lines: Heterogeneity of Autocrine Mechanism in TTC549. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 269-278.	1.7	13
131	Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki Disease. , 2000, 63, 160-161.		36
132	Neuronal Differentiation of Ewing's Sarcoma Induced by Cholera Toxin B and Bromodeoxyuridineâ€”Establishment of Ewing's Sarcoma Cell Line and Histochemical Studyâ€”. <i>Pediatrics International</i> , 1991, 33, 428-433.	0.2	5
133	Flowcytometric Analysis of DNA Pattern of Cells Derived from Xeroderma Pigmentosum Aâ€”Hypersensitivity to Vincristine, Etoposide and Methotrexateâ€”. <i>Pediatrics International</i> , 1990, 32, 262-268.	0.2	2
134	Restriction fragment length polymorphisms on the q24â€”q28 region of X chromosome among Japanese population. <i>Japanese Journal of Human Genetics</i> , 1989, 34, 123-128.	0.8	4
135	Restriction fragment length polymorphisms of X chromosome among Japanese population. <i>Japanese Journal of Human Genetics</i> , 1989, 34, 285-289.	0.8	0
136	A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20). <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	2